We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Study Finds Mutation Responsible for Accelerating Glioma Growth

An abstract image of a DNA double helix
Credit: Sangharsh Lohakare/ Unsplash

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Study Finds Mutation Responsible for Accelerating Glioma Growth"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

An important new clue for preventing and treating brain tumors known as gliomas has been identified in research led by the Lunenfeld-Tannenbaum Research Institute (LTRI) at Mount Sinai Hospital in Toronto and Mayo Clinic Comprehensive Cancer Center and Mayo Clinic Center for Individualized Medicine. The study, published in the journal Science, provides a rare window into the biological changes behind glioma development.


Researchers found that animal models who carry a change in DNA known as germline alteration rs55705857 developed gliomas much more frequently — and in half the time — compared to animal models without the alteration. In addition to brain tumors, the findings are relevant to other cancers and diseases.


"While we understand much of the biologic function of germline alterations within genes that code for proteins, we know very little about the biologic function of germline alterations outside of genes that code for proteins. In some way, these germline alterations interact with other mutations in cells to accelerate tumor formation," says co-lead author Robert Jenkins, M.D., Ph.D., a genetics researcher at Mayo Clinic in Rochester. "Based on this new understanding of its mechanism of action, future research may lead to novel and specific therapies that target the rs55705857 alteration."


The study offers new knowledge that may help clinicians determine, pre-surgery, whether a patient has a glioma.


"We expected that rs55705857 would accelerate low-grade glioma development, but we were surprised by the magnitude of that acceleration," says co-lead author Daniel Schramek, Ph.D., a researcher at Lunenfeld-Tannenbaum Research Institute.


There are many alterations, likely thousands, outside of genes associated with the development of cancer and other diseases, but the mechanism of action is only understood for very few, Dr. Schramek says.


This study demonstrates that, with the tools of modern molecular/cell biology, it is possible to decipher much of the mechanism of action of such alterations.


Reference: Yanchus C, Drucker KL, Kollmeyer TM, et al. A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science. 2022;378(6615):68-78. doi: 10.1126/science.abj2890


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement